Effect of ranolazine on improvement of heart functio
Phase 4
- Conditions
- Health Condition 1: null- Chronic stable angina
- Registration Number
- CTRI/2014/01/004332
- Lead Sponsor
- SRM Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Patients who have sustained STEMI more than 12 weeks ago.
2.Left ventricular ejection fraction <= 40%
3.Willing to give written informed consent and comply with all study related procedures
Exclusion Criteria
1.h/o undergoing CABG or stenting procedure within the last 12 weeks.
2.Co-existing end-stage pulmonary, or hepatic disease
3.Valvular heart disease
4.Patient consumed other study medication in the last 3 months.
5.Unwilling to comply with study related procedures
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in LV systolic and diastolic function as assessed by transthoracic EchocardiographyTimepoint: Changes in LV systolic and diastolic function before after 8 weeks of treatment with study drug
- Secondary Outcome Measures
Name Time Method 1.Improvement in angina symptoms <br/ ><br>2. ADRTimepoint: before and after 8 weeks of therapy